Arcutis Biotherapeutics Director Awarded Restricted Stock Units and Stock Options

Patrick J. Heron, a director of Arcutis Biotherapeutics, Inc., received 5,778 restricted stock units (RSUs) and 16,667 stock options on June 5, 2026. The RSUs represent a grant in connection with his service as a non-employee director at the company's 2026 annual meeting of stockholders. The RSUs will vest on the earlier of June 5, 2027 (one year from grant date) or immediately before the next annual meeting, subject to continued service. The stock options have an exercise price of $21.23 per share and expire on June 5, 2036, with similar vesting terms. Heron also holds indirect ownership in substantial common stock positions through various Frazier Life Sciences entities and a personal trust, totaling over 8.8 million shares across these indirect holdings.